Stockreport

US Rheumatologists Identify BAFF-R Inhibitors as the Most Promising Treatment Approach for Sjögren's Disease, According to Spherix Global Insights [Yahoo! Finance]

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares  (KNSA) 
Last kiniksa pharmaceuticals, ltd. - class a ordinary shares earnings: 8/12 04:02 pm Check Earnings Report
PDF EXTON, PA, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Sjögren's disease is a systemic autoimmune rheumatic condition that can profoundly affect a patient's overall functioning. [Read more]